Angiosarcoma is a rare cancer that affects the blood vessels. This malignant tumor poses a unique challenge in oncology. If not detected early, it can have devastating consequences. In Panama, angiosarcoma affects one person per million per year. It usually appears on the skin of the head and neck. However, it can develop anywhere in the body. Its aggressiveness and rapid spread make it difficult to treat. Patients and doctors face a great challenge in combating it. Knowing your symptoms can save lives. It is also important to understand effective diagnostic methods. We will explore the treatment options available for this vascular cancer.
What is Angiosarcoma and its main characteristics?
Angiosarcoma is a rare cancer that affects the blood and lymph vessels. It originates in the cells that line these vessels, called endothelial cells. It can develop in various parts of the body, with a preference for certain areas.
Definition and Types of Angiosarcoma
Angiosarcoma is a malignant tumor in the lining of blood and lymph vessels. There are several types, such as cutaneous, mammary, hepatic, and cardiac. Each type has unique characteristics and affects different organs.
Frequency and risk groups
This rare cancer accounts for between 1% and 2% of all sarcomas. About one case is diagnosed per million people a year in the United States. It is most common in people over 70 years of age. Exposure to radiation, chemicals, and certain genetic conditions can increase the risk.
Most common location in the body
Angiosarcoma can occur in several places in the body. The most common areas include:
- Skin, especially on the head and neck
- Breast
- Liver
- Spleen
- Heart (in rare cases associated with genetic mutations)
Cancer cells can invade and destroy nearby healthy tissues. The prognosis depends on the type and location of the tumor. Low-grade breast angiosarcoma usually has better survival.
Clinical manifestations and warning signs
Angiosarcoma is an aggressive cancer with varied symptoms. It originates in abnormal endothelial cells and affects different parts of the body. Its manifestations depend on the location of the tumor.
Symptoms on the skin and superficial tissues
On the skin, it appears as a raised, bruise-like lesion. This area grows over time and bleeds easily. There may be swelling in nearby tissues.
Symptoms in internal organs
In internal organs, symptoms are less obvious. Pain is common, but varies depending on the organ affected. In the liver, it can cause jaundice or abdominal pain.
When to seek immediate medical attention
Visit your doctor if you notice lesions that grow or bleed. Also if you feel unexplained pain in internal organs. Early diagnosis is key to effective treatment. Angiosarcoma accounts for 1% of cancers in adults. In children, it is more common, with 15% of cases. Early detection improves the prognosis and treatment of this aggressive cancer.
Professional medical diagnosis and evaluation
Diagnosing angiosarcoma requires a thorough medical evaluation. Your doctor will do a physical exam and order imaging tests. X-ray helps to see masses, while CT scans locate vascular neoplasms. The MRI shows the extent and location of the vascular cancer. Ultrasound differentiates cysts from solid tumors. Positron emission tomography (PET) scans detect glucose in cancer cells. To confirm the diagnosis, a biopsy is performed. There are types such as fine needle aspiration or core needling. The method depends on the size and location of the tumor. A pathologist examines the cells under a microscope to determine their malignant nature. Genetic testing identifies mutations associated with certain angiosarcomas. These tests help personalize treatment and improve prognosis.
Current Treatment Options Available
Treatment of angiosarcoma requires a multidisciplinary approach. For stage I tumors, surgery is the primary option. Postoperative radiation therapy reduces the chances of recurrence. In stages II and III, surgery is combined with radiation therapy. For more advanced tumors, chemotherapy is crucial. Medications such as doxorubicin and ifosfamide are common options. The prognosis for metastatic angiosarcomas is reserved. Median survival is 6 to 16 months. New targeted therapies and immunotherapy are under investigation. Angiosarcoma accounts for only 1-2% of all soft tissue sarcomas. This makes it challenging to manage. The 5-year survival rate varies between 30-40%.
